글로벌 비강 약물 전달 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

비강 약물 전달 시장 분석

비강 약물 투여 시장은 비침습적이고 효율적인 치료 옵션에 대한 수요 증가에 힘입어 강력한 성장을 경험하고 있습니다. 이 분야의 최근 발전은 약물 흡수와 환자 준수를 개선하는 고급 비강 스프레이 제형 및 비강 분말 투여 시스템과 같은 혁신 기술의 출현을 강조합니다. 예를 들어, Hovione과 같은 회사는 새로운 분말 투여 장치를 도입하여 비강 약물 투여 기능을 확장하여 비강 치료의 효능을 향상시켰습니다. 또한, 비강 투여 장치에 스마트 기술을 통합하여 실시간 모니터링 및 준수 추적을 가능하게 함으로써 환자 관리에 혁명을 일으키고 있습니다. 또한, 유리한 규제 승인과 함께 연구 개발에 대한 투자가 증가함에 따라 비강 약물 투여 환경에서 혁신과 확장이 촉진되어 궁극적으로 환자 결과와 만족도가 향상될 것으로 예상됩니다.

비강 약물 전달 시장 규모

글로벌 비강 약물 투여 시장 규모는 2023년에 6,542만 달러로 평가되었으며, 2031년까지 1억 1,157만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.90%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

비강 약물 전달 시장 동향

“ 나노입자 기반 비강 제형 의 새로운 용도 ”

비강 약물 전달 시장은 생체이용률과 환자 준수도를 향상시키는 새로운 제형과 전달 시스템 개발에 대한 상당한 추세를 보이고 있습니다. 시장의 한 가지 주요 추세는 나노 기술을 활용하여 비강 점막을 통한 약물 용해도와 흡수를 개선하는 나노입자 기반 비강 제형의 등장입니다. 예를 들어, 최근 연구에서는 항생제를 전달하는 데 나노에멀전 제형의 효과를 강조하여 기존 비강 스프레이에 비해 혈류에서 더 높은 농도를 달성했습니다. 이러한 추세는 천식 및 만성 폐쇄성 폐질환(COPD)과 같은 만성 호흡기 질환에 대한 효과적인 치료법에 대한 수요가 증가함에 따라 촉진되고 있으며, 이러한 질환에서는 빠른 작용이 중요합니다. 또한, 위장관을 우회하는 비강 투여의 편의성은 경구 약물에 어려움을 겪을 수 있는 환자에게 매력적입니다. 결과적으로 비강 약물 전달 시장에서 나노입자 기술을 채택하면 치료 효능과 환자 선호도에 모두 부응하여 성장과 혁신이 촉진될 것으로 예상됩니다.

보고서 범위 및 비강 약물 전달 시장 세분화

Nasal Drug Delivery Market Definition

Nasal drug delivery refers to the administration of pharmaceutical substances through the nasal cavity, allowing for rapid absorption into the systemic circulation or localized effects within the nasal passages. This route of administration leverages the rich vascularization and permeability of the nasal mucosa to bypass the gastrointestinal tract and hepatic first-pass metabolism, resulting in enhanced bioavailability and quicker onset of action. Nasal drug delivery systems can include various formulations such as nasal sprays, drops, gels, and powders, designed to deliver a wide range of therapeutic agents, including medications for conditions like allergies, asthma, pain relief, and vaccines. This method is particularly advantageous for patients who may have difficulty swallowing pills or require immediate therapeutic effects.

Nasal Drug Delivery Market Dynamics

Drivers

• Increasing Prevalence of Respiratory Diseases

The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis is a key driver in the growth of the nasal drug delivery market. According to the World Health Organization (WHO), asthma alone affects an estimated 262 million people globally, leading to a significant demand for quick and effective treatment options. In addition, COPD, which is responsible for 3.23 million deaths annually, is projected to become the third leading cause of death worldwide by 2030. The rising prevalence of allergic rhinitis, affecting between between 10-30% of adults and over 40% of children globally, further emphasizes the need for advanced nasal drug delivery systems. Such conditions require rapid-onset treatments, and nasal sprays or powders offer fast absorption into the bloodstream, providing immediate relief. As a result, the increasing global burden of respiratory diseases continues to drive the expansion of the nasal drug delivery market, offering substantial opportunities for manufacturers to develop effective solutions.

• Growing Preference for Non-Invasive Administration Methods

The growing preference for non-invasive administration methods is emerging as a major driver in the nasal drug delivery market. Nasal delivery systems provide a convenient alternative to injections and oral medications, which many patients find uncomfortable or challenging, with needle anxiety prevalence ranging from 17% to 52% among adults. In addition, oral medications pose difficulties for patients who struggle with swallowing, particularly older populations, where dysphagia affects up to 22% of people over 50 years of age. Nasal drug delivery systems, such as sprays and powders, offer a painless and easy-to-use solution that bypasses these challenges, improving patient compliance and enhancing treatment outcomes. Such shift in preference toward non-invasive options is accelerating the adoption and development of nasal drug delivery systems, thus driving market growth.

Opportunities

• Increasing Advancements in Formulation Technologies

Advancements in formulation technologies, such as the development of mucoadhesive polymers, are significantly enhancing the efficacy of nasal drug delivery by improving drug stability, bioavailability, and absorption. Mucoadhesive polymers adhere to the nasal mucosa, increasing the retention time of the drug and promoting better absorption. For example, chitosan-based nasal formulations have shown improved absorption of peptides and proteins, making them particularly effective for delivering large molecules like insulin. Studies indicate that using mucoadhesive polymers in nasal formulations can increase drug bioavailability by a notable percentage, offering more efficient delivery of medications. Such innovations present significant opportunities for pharmaceutical companies to develop more effective nasal formulations, improving treatment outcomes for various conditions, including chronic diseases.

• Increasing Availability of Nasal Drugs

The increasing availability of nasal drugs presents a significant opportunity in the global nasal drug delivery market. As more pharmaceutical companies develop and market nasal formulations, access to these medications has expanded, making them more widely available for various treatments. For instance, nasal sprays are now commonly used for conditions ranging from allergic rhinitis and migraines to emergency treatments such as naloxone for opioid overdoses. In addition, with the rise of e-commerce and online pharmacies, nasal drugs are becoming easier to obtain, especially in regions where access to healthcare facilities may be limited. The growing adoption of nasal delivery systems is also fueled by their convenience and rapid onset of action, offering an appealing alternative to traditional oral or injectable treatments. This expanding accessibility creates a promising growth opportunity for the nasal drug delivery market globally.

Restraints/Challenges

• Rigorous Clinical Trials, Safety Assessments, and Regulatory Approvals

The nasal drug delivery market faces substantial challenges due to the need for rigorous clinical trials, safety assessments, and regulatory approvals, which can significantly delay the introduction of innovative products. Developing new nasal formulations often requires extensive preclinical and clinical studies to ensure efficacy and safety, particularly given the sensitive nature of nasal mucosa and potential adverse reactions. Such lengthy approval processes can deter investment from smaller companies and startups, limiting their ability to innovate and compete in the market. In addition, the evolving regulatory landscape necessitates continuous adaptation by manufacturers to comply with updated guidelines, which can further hinder market entry for novel nasal drug delivery solutions, thereby restricting the availability of effective therapies for patients with respiratory conditions.

• Overuse of Nasal Sprays

The nasal drug delivery market is grappling with significant challenges due to the overuse of nasal sprays, particularly those containing decongestants like oxymetazoline and phenylephrine. Prolonged use of these sprays can lead to rhinitis medicamentosa, or rebound congestion, where patients experience worsening nasal congestion once the effects wear off. Such effects erodes consumer trust in nasal spray products. Consequently, the prevalence of rebound congestion poses a substantial challenge for the nasal drug delivery market, as it may deter patients from utilizing these treatments effectively.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Nasal Drug Delivery Market Scope

The market is segmented on the basis of drug type, dosage form, container type, system type, therapeutic application, distribution channel, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Anaesthetics
• Antibiotics
• Pain Relief Drugs
• Calcium Supplements
• Vasoconstrictors
• Antihistamines
• Others

Dosage Form

• Nasal Spray
• Nasal Drops
• Nasal Gels and Ointments
• Nasal Powders
• Others

Container Type

• Non-Pressurized Containers
• Pressurized Containers

System Type

• Multi-Dose
• Bi-Dose
• Unit Dose

Therapeutic Application

• Allergic and Non-Allergic Rhinitis
• Nasal Congestion
• Asthma
• Vaccination
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End User

• Hospitals
• Clinics
• Home Care Settings

Nasal Drug Delivery Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug type, dosage form, container type, system type, therapeutic application, distribution channel, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global nasal drug delivery market, primarily due to the concentration of major industry players and a robust healthcare infrastructure that supports innovation and accessibility. The region has seen a notable rise in the prevalence of conditions such as rhinitis, sinusitis, nasal congestion, and respiratory allergies, which significantly drives demand for effective nasal drug delivery solutions. Furthermore, advancements in research and development, alongside increased awareness of nasal delivery methods among healthcare professionals and patients, are expected to enhance the market's growth trajectory in North America over the coming years.

Asia-Pacific region is projected to experience substantial growth from 2024 to 2031, driven by an increasing geriatric population and a surge in allergy-related diseases. This demographic shift, coupled with rising healthcare awareness and accessibility, is contributing to the demand for effective pulmonary drug delivery systems. In addition, the growing prevalence of environmental factors that exacerbate allergic conditions further underscores the need for advanced therapeutic solutions in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Nasal Drug Delivery Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

시장에서 운영되는 비강 약물 전달 시장 리더는 다음과 같습니다.

• 머크앤코(미국)
• GSK plc (영국)
• 아스트라제네카(영국)
• 존슨앤존슨 서비스 주식회사(미국)
• 미스틱제약(미국)
• Bausch Health Companies Inc. (캐나다)
• BD(미국)
• 3M(미국)
• AptarGroup, Inc. (미국)
• OptiNose US, Inc. (미국)
• Dr. Reddy's Laboratories Ltd(인도)
• Aspen Group, Inc. (호주)
• 카딜라 파마슈티컬스(인도)
• 펜도팜(캐나다)
• Neurelis, Inc. (미국)

비강 약물 전달 시장의 최신 개발

• 2023년 11월, 호비온은 IDC와 협력하여 개발한 혁신적인 비강 분말 전달 장치를 출시하여 비강 약물 전달 기능을 확장한다고 발표했습니다. 비강 약물 전달은 단순성, 안전성 및 빠른 작용 시작 덕분에 국소 및 전신 치료 모두에 대한 기존 전달 방법에 대한 실행 가능한 대안을 제공합니다.
• 2021년 7월, GSKl plc는 미국 식품의약국(FDA)이 비강 용종이 있는 만성 비강염 환자를 위해 특별히 설계된 단일 클론 항체인 Nucala(mepolizumab)에 대한 승인을 내렸다고 발표했습니다. 이 획기적인 승인은 이 질환에 걸린 개인을 위한 치료 옵션에서 상당한 진전을 나타내며, 증상을 완화하고 삶의 질을 개선하는 데 도움이 되는 표적 치료법을 제공합니다.

SKU-26020